Inhibrx reports Q3 2026 financial results with $199.5M cash
Inhibrx reported Q3 2026 revenue of $2.0M under a Pfizer license and $199.5M in cash, advancing a pipeline of clinical trials for ozekibart and ordastobart.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed